Asset profile
Semzuvolimab
Monoclonal antibody
Evidence outlook · registrational
HIV: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. The registry's posted readout date (2026-06-30) has passed without a status update. Check News for topline announcements.
NCT04404049: This is a small, open-label randomized study comparing two dosing schedules of add-on Semzuvolimab against standard therapy alone in people already on antiretroviral therapy. The primary measure is treatment-related side effects rather than a virologic or clinical outcome, and results are not yet available, so the evidence for Semzuvolimab's clinical benefit cannot yet be assessed.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 59 same-indication; 21 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Semzuvolimab: this drug | Phase 3 | Monoclonal antibody | CD4 receptor | ||
| Ibalizumab (Trogarzo) | Approved | Monoclonal antibody | CD4 receptor | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | ||
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | Small molecule | HIV integrase | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elvitegravir (Stribild / Genvoya (component)) | Approved | Small molecule | HIV integrase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase | ||
| Etravirine (Intelence) | Approved | Small molecule | HIV reverse transcriptase | ||
| Fosamprenavir (Lexiva / Telzir) | Approved | Small molecule | HIV protease | ||
| Fostemsavir (Rukobia) | Approved | Small molecule | HIV gp120 | ||
| Lenacapavir (Sunlenca / Yeztugo) | Approved | Small molecule | HIV capsid | ||
| Maraviroc (Selzentry / Celsentri) | Approved | Small molecule | CCR5 co-receptor |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.